B cell receptor (BCR) sequencing panel is used to detect the rearrangement of human B lymphocyte receptor gene in relative quantitation. The results of this assay mainly assist the diagnosis of ALL, MM and CLL by detecting BCR gene rearrangement, so as to facilitate clinicians to make more accurate assessment and right treatment of patients in combination with other test results. For hematological malignancies, Minimal/measurable/molecule residual disease ( MRD) testing can be used for risk stratification, efficacy assessment, recurrence monitoring, and clonal evolution tracking.
• High sensitivity: Sensitivity as high as 0.0001%
• Broad applications: Suitable for B-ALL, MM and CLL patients
• Detection of new clones: Identifications of clone evolutions, immune recovery, and immune reconstitution
• Excellent repeatability: Standardarizedexperimental process and bioinformatics analysis
Applicable disease type |
Specimen type |
Acute B lymphoblastic leukemia (B-ALL) |
Bone marrow or peripheral blood |
Multiple myeloma (MM) |
Bone marrow or peripheral blood |
Chronic lymphocytic leukemia (CLL) |
Bone marrow or peripheral blood |
Specimen |
Volume |
Shipping conditions |
|
Before treatment |
Bone marrow (fresh) |
1mL |
4 ℃,48h |
Peripheral blood (fresh) |
2-3mL |
4 ℃,48h |
|
DNA |
2ug |
Dry ice , 48h |
Specimen |
Volume |
Shipping conditions |
|
After treatment |
Bone marrow (fresh) |
2-3mL |
4℃, 48h |
Peripheral blood (fresh) |
>5mL |
4℃, 48h |
|
DNA |
>7ug |
Dry ice, 48h |
Sensitivity |
DNA Amount (ug) |
10-4 |
2ug |
10-5 |
7ug |
10-6 |
20ug |
If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.
1. Customized or bulk orders of IVD/CDx products.
2. Get a quote for IVD/CDx products
3. Become our distributor
4. Get customized pharmaceutical service solutions
5.Learn more about our technology and R&D
Show of MEDx by CCTV